8-K: BioAge Labs Announces First Quarter 2025 Financial Results and Business Updates, Including Lilly Collaboration and NLRP3 Inhibitor Progress

BioAge Labs reports its Q1 2025 financial results, highlights progress on its BGE-102 NLRP3 inhibitor, announces a new collaboration with Lilly, and advances its APJ agonist program.

Summary

• BioAge Labs reported its first quarter 2025 financial results, showcasing advancements in its pipeline and strategic collaborations.
• The company's lead candidate, BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, is progressing with initial clinical data expected in the second half of 2025.
• A new strategic collaboration with Lilly ExploR&D expands BioAge's therapeutic approach to novel metabolic aging targets.
• Preclinical development of next-generation APJ agonists for obesity is also advancing.
• Research and development expenses for the quarter were $11.1 million, compared to $9.3 million in the same period of 2024.
• General and administrative expenses were $6.8 million, compared to $3.5 million in the same period of 2024.
• The net loss for the quarter was $12.9 million, or $0.36 per share, compared to a net loss of $13.0 million, or $7.76 per share, for the same period in 2024.
• As of March 31, 2025, BioAge had approximately $335.1 million in cash, cash equivalents, and marketable securities.
• The company estimates that its current financial resources will be sufficient to fund operations and capital expenses through 2029.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's strong cash position, progress in its pipeline, and strategic collaboration with Lilly. However, the net loss and increased expenses temper the overall sentiment.

Positives

• BioAge has a strong cash position of $335.1 million, which is expected to fund operations through 2029.
• The company is advancing its lead candidate, BGE-102, towards clinical trials with initial data expected in the second half of 2025.
• The strategic collaboration with Lilly validates BioAge's platform-driven approach to targeting the biology of aging.
• The company is making meaningful progress in its research collaboration with Novartis.

Negatives

• The company experienced a net loss of $12.9 million for the quarter ended March 31, 2025.
• General and administrative expenses increased by $3.3 million compared to the same period in 2024, primarily due to increased personnel-related expenses and stock-based compensation.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include the ability to develop, obtain regulatory approval for, and commercialize product candidates, as well as the timing and results of preclinical studies and clinical trials.
• There are risks associated with clinical trials, including the ability to adequately manage clinical activities and the potential for unexpected concerns to arise from additional data or analysis.
• The company's dependence on collaborators and other third parties for the development of product candidates is also a risk factor.

Future Outlook

BioAge estimates that its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029, and the company anticipates initial Phase 1 data for BGE-102 in the second half of 2025.

Management Comments

• Kristen Fortney, Ph.D., CEO and co-founder of BioAge, stated that the first quarter of 2025 was marked by strategic execution as the company advanced its focused pipeline.
• She also mentioned the significant progress with BGE-102 and the expectation of initial Phase 1 data before year-end.
• Fortney highlighted the new collaboration with Lilly, which expands the company's therapeutic capabilities into antibodies and validates its platform-driven approach to targeting the biology of aging.

Industry Context

BioAge's focus on metabolic diseases and the biology of aging aligns with growing interest in longevity research and treatments for age-related conditions. The collaboration with Lilly, a major pharmaceutical company, signals increasing validation of this approach. The development of NLRP3 inhibitors and APJ agonists places BioAge in a competitive landscape with other companies pursuing similar targets for obesity and related metabolic disorders.

Comparison to Industry Standards

• BioAge's collaboration with Lilly is similar to other partnerships in the biotech industry where smaller companies with innovative platforms collaborate with larger pharmaceutical companies to accelerate drug development.
• The $335.1 million in cash is a strong financial position for a clinical-stage biotech company, providing runway to advance its pipeline.
• Other companies in the metabolic disease space, such as Viking Therapeutics and Amgen, are also developing novel therapies for obesity and related conditions, setting a competitive benchmark for efficacy and safety.

Stakeholder Impact

• Shareholders may be positively impacted by the company's progress in its pipeline and strategic collaborations.
• Employees may benefit from the company's growth and development opportunities.
• Patients with metabolic diseases may benefit from the development of new therapies.

Next Steps

• Continue IND-enabling studies for BGE-102.
• Initiate Phase 1 clinical trial for BGE-102, with initial data expected in the second half of 2025.
• Advance the portfolio of novel APJ agonists for obesity, with the goal of nominating a development candidate by the end of 2025.
• Continue the research collaboration with Novartis.
• Advance the strategic collaboration with Lilly ExploR&D to develop therapeutic antibodies targeting novel metabolic aging targets.

Key Dates

Keywords

BioAge Labs, NLRP3 inhibitor, BGE-102, Lilly ExploR&D, APJ agonists, metabolic diseases, obesity, financial results, clinical trials, aging biology